Company / Depreciation & Amortization
CytomX Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.2M
FY2025
5-year range
$1.2M / $2.6M
FY2021-FY2025
Trend
-25.0%
vs FY2024
Sector context
#121 of 168
Health Care
What the data says
At $1M, CytomX Therapeutics, Inc.'s depreciation & amortization ranks #48 of 168 in the Health Care sector. Depreciation & Amortization has declined for 4 consecutive years, from $3M in FY2021 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of -19.5%.
Improved from $2M to $1M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -19.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#48 of 168 in Health CareTop 28% of 168This company $1.2M Sector average $212.9M
▼
-99.4% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s depreciation & amortization has declined for 4 consecutive years.
- 3-year CAGR of -19.5%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 25.0% year-over-year.
- Ranks #121 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | -25.0% |
| FY2024 | $1.6M | -20.0% |
| FY2023 | $2.0M | -13.0% |
| FY2022 | $2.3M | -11.5% |
| FY2021 | $2.6M | - |
| FY2020 | - | - |
| FY2019 | $2.5M | +47.1% |
| FY2018 | $1.7M | +13.3% |
| FY2017 | $1.5M | -13.4% |
| FY2016 | $1.7M | +164.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026